Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.49 |
| ▸ | PIM1 | P11309 | 4/20 | 0.49 |
| ▸ | PIM2 | Q9P1W9 | 4/20 | 0.49 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.49 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.45 |
| ▸ | TTR | P02766 | 1/20 | 0.44 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.44 |
| ▸ | ESRRA | P11474 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2425656 | 1.00 | GPR119 (0.49) | GPR119PIM1PIM2PIM3NR1H4 | |
| SCHEMBL13537962 | 0.94 | GPR119 (0.49) | GPR119PIM1PIM2PIM3NR1H4 | |
| SCHEMBL2426618 | 0.89 | PIM1 (0.45) | GPR119PIM1PIM2PIM3NR1H4 | |
| SCHEMBL2426616 | 0.89 | PIM1 (0.45) | GPR119PIM1PIM2PIM3NR1H4 | |
| SCHEMBL12282967 | 0.87 | GPR119 (0.51) | GPR119PIM1PIM2PIM3NR1H4 | |
| SCHEMBL2423844 | 0.85 | PIM1 (0.48) | PIM1PIM2PIM3NR1H4PTPN1 | |
| SCHEMBL2423842 | 0.85 | PIM1 (0.48) | PIM1PIM2PIM3NR1H4PTPN1 | |
| SCHEMBL2424864 | 0.84 | PIM1 (0.66) | GPR119PIM1PIM2PIM3TTR | |
| SCHEMBL2428104 | 0.84 | PIM1 (0.66) | GPR119PIM1PIM2PIM3TTR | |
| SCHEMBL12282352 | 0.82 | PIM1 (0.46) | PIM1PIM2PIM3NR1H4PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150051185-A1 | Chemical Compounds 251 | ASTRAZENECA AB (SE) | 2015-02-19 | — | — | US | disclosed |
| US-8901307-B2 | Chemical compounds 251 | ASTRAZENECA AB (SE) | 2014-12-02 | — | — | US | disclosed |
| US-20110218182-A1 | CHEMICAL COMPOUNDS 251 | ASTRAZENECA AB (SE) | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218182-A1 | CHEMICAL COMPOUNDS 251 | PIM1, PIM3, PIM2 | GPR119 1748/4885PIM1 1/4885PIM2 3/4885 |
| US-20150051185-A1 | Chemical Compounds 251 | PIM1, PIM3, PIM2 | GPR119 1733/4885PIM1 1/4885PIM2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.